Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials
June 07, 2022 09:04 ET
|
Qualigen Therapeutics, Inc.
A Potential Treatment for Pancreatic Cancer in Addition to Other Tumors of High Unmet Clinical Need CARLSBAD, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq:...
Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex
June 02, 2022 09:00 ET
|
Qualigen Therapeutics, Inc.
Transaction expected to significantly advance commercial readiness of NanoSynex’s innovative diagnostics technology platform focused on the $30+ Billion global infectious disease testing market ...
Qualigen Therapeutics’ Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting
May 26, 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
Abstracts Highlight In Vitro and In Vivo Activity of Qualigen’s Pan-RAS inhibitor in (1) Pancreatic Cancer, and (2) Malignant Peripheral Nerve Sheath Tumors CARLSBAD, Calif., May 26, 2022 (GLOBE...
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 20, 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 13, 2022 06:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics’ Partner NanoSynex to Present Technology at BioMed Israel
May 10, 2022 09:17 ET
|
Qualigen Therapeutics, Inc.
Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a...
Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex
May 03, 2022 09:17 ET
|
Qualigen Therapeutics, Inc.
Companies to Collaborate in the Development of Innovative Diagnostics Platform to Combat “Superbugs,” a Rising Global Health Crisis CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Qualigen...
Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President
April 29, 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference
April 12, 2022 10:15 ET
|
Qualigen Therapeutics, Inc.
Data Highlights In Vivo Research and the Potential Mechanism of Action in Pancreatic and Prostate Cancers CARLSBAD, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc....
Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack®
April 05, 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
Company Prepared for Growth and Improved Profitability of its Diagnostics Business CARLSBAD, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...